Targeted immunoglobulin therapy for the prevention of neonatal infection

R. M. Kliegman, D. Clapp, M. Berger

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Premature infants demonstrate hypoglobulinemia and are at increased risk for serious infections. Although a cause-and-effect relation between low serum IgG levels and neonatal infections has not been established, prophylaxis of such severe infections may be possible by replacement of antibody with intravenous immunoglobulin (IVIG). For success, IVIG must provide specific antibodies to neonatal pathogens and reach therapeutic serum IgG target levels. Pilot investigations have demonstrated that IVIG reduces the incidence of bacterial sepsis among premature infants. Infants received IVIG every 2 weeks (or more frequently) until they weighted 2,000 g. Serum IgG levels were monitored after each dose so that the dose could be adjusted to achieve a target IgG level >700 mg/dL. The observation that infection among placebo-treated patients occurred when the serum IgG level declined to <400 mg/dL suggests the importance of achieving a target level. In our preliminary analysis, the IVIG used did not reduce the incidence of infection with respiratory syncytial virus (RSV) and rotavirus or of necrotizing enterocolitis. That the lot of IVIG used did not contain significant antibody to RSV or rotavirus emphasizes the improtance of pathogen-specific antibody. Because of the preliminary nature of these results and the potential for undetermined short-term and long-term sequelae, we do not recommend the indiscriminant use of IVIG for prevention or treatment of neonatal infections.

Original languageEnglish (US)
JournalReviews of Infectious Diseases
Volume12
Issue numberSUPPL. 4
StatePublished - 1990
Externally publishedYes

Fingerprint

Passive Immunization
Intravenous Immunoglobulins
Immunoglobulin G
Infection
Antibodies
Rotavirus
Serum
Premature Infants
Respiratory Syncytial Virus Infections
Necrotizing Enterocolitis
Respiratory Syncytial Viruses
Incidence
Sepsis
Placebos
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Targeted immunoglobulin therapy for the prevention of neonatal infection. / Kliegman, R. M.; Clapp, D.; Berger, M.

In: Reviews of Infectious Diseases, Vol. 12, No. SUPPL. 4, 1990.

Research output: Contribution to journalArticle

@article{55b7002b8fc440478f4242b16c377c8d,
title = "Targeted immunoglobulin therapy for the prevention of neonatal infection",
abstract = "Premature infants demonstrate hypoglobulinemia and are at increased risk for serious infections. Although a cause-and-effect relation between low serum IgG levels and neonatal infections has not been established, prophylaxis of such severe infections may be possible by replacement of antibody with intravenous immunoglobulin (IVIG). For success, IVIG must provide specific antibodies to neonatal pathogens and reach therapeutic serum IgG target levels. Pilot investigations have demonstrated that IVIG reduces the incidence of bacterial sepsis among premature infants. Infants received IVIG every 2 weeks (or more frequently) until they weighted 2,000 g. Serum IgG levels were monitored after each dose so that the dose could be adjusted to achieve a target IgG level >700 mg/dL. The observation that infection among placebo-treated patients occurred when the serum IgG level declined to <400 mg/dL suggests the importance of achieving a target level. In our preliminary analysis, the IVIG used did not reduce the incidence of infection with respiratory syncytial virus (RSV) and rotavirus or of necrotizing enterocolitis. That the lot of IVIG used did not contain significant antibody to RSV or rotavirus emphasizes the improtance of pathogen-specific antibody. Because of the preliminary nature of these results and the potential for undetermined short-term and long-term sequelae, we do not recommend the indiscriminant use of IVIG for prevention or treatment of neonatal infections.",
author = "Kliegman, {R. M.} and D. Clapp and M. Berger",
year = "1990",
language = "English (US)",
volume = "12",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Targeted immunoglobulin therapy for the prevention of neonatal infection

AU - Kliegman, R. M.

AU - Clapp, D.

AU - Berger, M.

PY - 1990

Y1 - 1990

N2 - Premature infants demonstrate hypoglobulinemia and are at increased risk for serious infections. Although a cause-and-effect relation between low serum IgG levels and neonatal infections has not been established, prophylaxis of such severe infections may be possible by replacement of antibody with intravenous immunoglobulin (IVIG). For success, IVIG must provide specific antibodies to neonatal pathogens and reach therapeutic serum IgG target levels. Pilot investigations have demonstrated that IVIG reduces the incidence of bacterial sepsis among premature infants. Infants received IVIG every 2 weeks (or more frequently) until they weighted 2,000 g. Serum IgG levels were monitored after each dose so that the dose could be adjusted to achieve a target IgG level >700 mg/dL. The observation that infection among placebo-treated patients occurred when the serum IgG level declined to <400 mg/dL suggests the importance of achieving a target level. In our preliminary analysis, the IVIG used did not reduce the incidence of infection with respiratory syncytial virus (RSV) and rotavirus or of necrotizing enterocolitis. That the lot of IVIG used did not contain significant antibody to RSV or rotavirus emphasizes the improtance of pathogen-specific antibody. Because of the preliminary nature of these results and the potential for undetermined short-term and long-term sequelae, we do not recommend the indiscriminant use of IVIG for prevention or treatment of neonatal infections.

AB - Premature infants demonstrate hypoglobulinemia and are at increased risk for serious infections. Although a cause-and-effect relation between low serum IgG levels and neonatal infections has not been established, prophylaxis of such severe infections may be possible by replacement of antibody with intravenous immunoglobulin (IVIG). For success, IVIG must provide specific antibodies to neonatal pathogens and reach therapeutic serum IgG target levels. Pilot investigations have demonstrated that IVIG reduces the incidence of bacterial sepsis among premature infants. Infants received IVIG every 2 weeks (or more frequently) until they weighted 2,000 g. Serum IgG levels were monitored after each dose so that the dose could be adjusted to achieve a target IgG level >700 mg/dL. The observation that infection among placebo-treated patients occurred when the serum IgG level declined to <400 mg/dL suggests the importance of achieving a target level. In our preliminary analysis, the IVIG used did not reduce the incidence of infection with respiratory syncytial virus (RSV) and rotavirus or of necrotizing enterocolitis. That the lot of IVIG used did not contain significant antibody to RSV or rotavirus emphasizes the improtance of pathogen-specific antibody. Because of the preliminary nature of these results and the potential for undetermined short-term and long-term sequelae, we do not recommend the indiscriminant use of IVIG for prevention or treatment of neonatal infections.

UR - http://www.scopus.com/inward/record.url?scp=0025286366&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025286366&partnerID=8YFLogxK

M3 - Article

VL - 12

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 4

ER -